Kristin Stephens - Mar 31, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Chief Development Officer
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Mar 31, 2023
Transactions value $: -$1,607
Form type: 4
Date filed: 4/4/2023, 06:55 PM
Previous filing: Feb 21, 2023
Next filing: Nov 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Options Exercise		+2K	+64.77%		5.09K	Mar 31, 2023	Direct	F1, F2
transaction	SYRS	Common Stock	Tax liability	-$1.61K	-623	-12.24%	$2.58	4.47K	Apr 3, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Restricted Stock Units	Options Exercise	$0	-2K	-25%	$0.00	6K	Mar 31, 2023	Common Stock	2K		Direct	F2, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	On September 16, 2022, the issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3	Represents shares used to cover tax withholding on a restricted stock unit release.
F4	Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F5	Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.